Efficacy and safety of trilaciclib to prevent chemotherapy-induced myelosuppression in advanced solid tumors: a systematic review and meta-analysis
{{output}}
Background: Trilaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that has shown promise in mitigating chemotherapy-induced myelosuppression (CIM). This meta-analysis aims to provide a comprehensive and clinically r... ...
